Intestinal MUC2 and gastric M1/MUC5AC in preneoplastic lesions induced by 1,2-dimethylhydrazine in rat: A sequential analysis

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 489-497

  Zoghbi, Sandra ^a   Drouin, Emeline ^a   Claustre, Jean ^a   Bara, Jacques ^c   Scoazec, Jean Yves ^a   Plaisancié, Pascale ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b CEMAGREF   (France)

^c INSERM   (France)

Author keywords

Aberrant crypt foci; Colorectal cancer; Mucin; catenin

Indexed keywords

1,2 DIMETHYLHYDRAZINE; BETA CATENIN; CARCINOGEN; MUC 2 PROTEIN; MUCIN; MUCIN 5AC; UNCLASSIFIED DRUG;

ADENOMA; ANIMAL; ARTICLE; BIOSYNTHESIS; CARCINOMA; COLON; FISCHER 344 RAT; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; PRECANCER; RAT; TUMOR CELL LINE;

1,2-DIMETHYLHYDRAZINE; ADENOMA; ANIMALS; BETA CATENIN; CARCINOGENS; CARCINOMA; CELL LINE, TUMOR; COLON; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUCINS; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344;

EID: 34047261442     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Roncucci L, Medline A and Bruce WR: Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol Biomarkers Prev 1: 57-60, 1991.
2. Nascimbeni R, Donato F, Ghirardi M, Mariani P, Villanacci V and Salerni B: Constipation, anthranoid laxatives, melanosis coli, and colon cancer: a risk assessment using aberrant crypt foci. Cancer Epidemiol Biomarkers Prev 11: 753-757, 2002.
3. Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37: 147-151, 1987.
4. Lasko CM and Bird RP: Modulation of aberrant crypt foci by dietary fat and caloric restriction: the effects of delayed intervention. Cancer Epidemiol Biomarkers Prev 4: 49-55, 1995.
5. Wargovich MJ, Chen CD, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K and Kelloff GJ: Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 5: 355-360, 1996.
6. Alrawi SJ, Schiff M, Carroll RE, Dayton M, Gibbs JF, Kulavlat M, Tan D, Berman K, Stoler DL and Anderson GR: Aberrant crypt foci. Anticancer Res 26: 107-119, 2006.
7. Yamada Y and Mori H: Pre-cancerous lesions for colorectal cancers in rodents: a new concept. Carcinogenesis 24: 1015-1019, 2003.
8. Mori H, Yamada Y, Kuno T and Hirose Y: Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis. Mutat Res 566: 191-208, 2004.
9. Hao XP, Pretlow TG, Rao JS and Pretlow TP: Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 61: 8085-8088, 2001.
10. Corpet DE and Pierre F: Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 12: 391-400, 2003.
11. Corpet DE and Tache S: Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 43: 1-21, 2002.
12. Hirose Y, Kuno T, Yamada Y, Sakata K, Katayama M, Yoshida K, Qiao Z, Hata K, Yoshimi N and Mori H: Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 24: 107-111, 2003.
13. Caderni G, Femia AP, Giannini A, Favuzza A, Luceri C, Salvadori M and Dolara P: Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 63: 2388-2392, 2003.
14. Femia AP, Dolara P and Caderni G: Mucin-depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are useful biomarkers for colon carcinogenesis. Carcinogenesis 25: 277-281, 2004.
15. Porchet N, Buisine MP, Desseyn JL, Moniaux N, Nollet S, Degand P, Pigny P, van Seuningen I, Laine A and Aubert JP: MUC genes: a superfamily of genes? Towards a functional classification of human apomucins. J Soc Biol 193: 85-99, 1999.
16. Escande F, Porchet N, Bernigaud A, Petitprez D, Aubert JP and Buisine MP: The mouse secreted gel-forming mucin gene cluster. Biochim Biophys Acta 1676: 240-250, 2004.
17. Audie JP, Janin A, Porchet N, Copin MC, Gosselin B and Aubert JP: Expression of human mucin genes in respiratory, digestive, and reproductive tracts ascertained by in situ hybridization. J Histochem Cytochem 41: 1479-1485, 1993.
18. Blank M, Klussmann E, Kruger-Krasagakes S, et al: Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types. Int J Cancer 59: 301-306, 1994.
19. Hanski C, Riede E, Gratchev A, Foss HD, Bohm C, Klussmann E, Hummel M, Mann B, Buhr HJ, Stein H, Kim YS, Gum J and Riecken EO: MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation. Lab Invest 77: 685-695, 1997.
20. Sylvester PA, Myerscough N, Warren BF, Carlstedt I, Corfield AP, Durdey P and Thomas MG: Differential expression of the chromosome 11 mucin genes in colorectal cancer. J Pathol 195: 327-335, 2001.
21. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K and Augenlicht L: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295: 1726-1729, 2002.
22. Bara J, Languille O, Gendron MC, Daher N, Martin E and Burtin P: Immunohistological study of precancerous mucus modification in human distal colonic polyps. Cancer Res 43: 3885-3891, 1983. (Pubitemid 13077719)
23. Decaens C, Bara J, Rosa B, Daher N and Burtin P: Early oncofetal antigenic modifications during rat colonic carcinogenesis. Cancer Res 43: 355-362, 1983.
24. Bara J, Nardelli J, Gadenne C, Prade M and Burtin P: Differences in the expression of mucus-associated antigens between proximal and distal human colon adenocarcinomas. Br J Cancer 49: 495-501, 1984.
25. Bara J, Forgue-Lafitte ME, Maurin N, Flejou JF and Zimber A: Abnormal expression of gastric mucin in human and rat aberrant crypt foci during colon carcinogenesis. Tumour Biol 24: 109-115, 2003.
26. Decaens C, Gautier R, Bara J, Daher N, Le Pendu J and Burtin P: A new mucin-associated oncofetal antigen, a marker of early carcinogenesis in rat colon. Cancer Res 48: 1571-1577, 1988.
27. Bird RP: Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 93: 55-71, 1995.
28. Bara J, Andre J, Gautier R and Burtin P: Abnormal pattern of mucus-associated M1 antigens in histologically normal mucosa adjacent to colonic adenocarcinomas. Cancer Res 44: 4040-4045, 1984.
29. Decaens C, Nardelli J, Bara J and Burtin P: Biochemical characterization of a rat oncofetal colonic antigen defined by a monoclonal antibody raised against gastric surface epithelium. Biochem J 293: 531-536, 1993.
30. Roger P, Gascard JP, Bara J, De Montpreville VT, Yeadon M and Brink C: ATP induced MUC5AC release from human airways in vitro. Mediators Inflamm 9: 277-284, 2000.
31. Roger P, Gascard JP, Bara J, De Montpreville VT and Brink C: MUC5AC mucin release from human airways in vitro: effects of indomethacin and Bay X1005. Mediators Inflamm 10: 33-36, 2001.
32. Plaisancie P, Barcelo A, Moro F, Claustre J, Chayvialle JA and Cuber JC: Effects of neurotransmitters, gut hormones, and inflammatory mediators on mucus discharge in rat colon. Am J Physiol 275: G1073-G1084, 1998.
33. Weiss AA, Babyatsky MW, Ogata S, Chen A and Itzkowitz SH: Expression of MUC2 and MUC3 mRNA in human normal, malignant, and inflammatory intestinal tissues. J Histochem Cytochem 44: 1161-1166, 1996.
34. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R and Kim YS: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53: 641-651, 1993.
35. Chang SK, Dohrman AF, Basbaum CB, Ho SB, Tsuda T, Toribara NW, Gum JR and Kim YS: Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. Gastroenterology 107: 28-36, 1994.
36. Behrens J: The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem Soc Trans 33: 672-675, 2005.
37. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, Clevers H and Jay P: SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 166: 37-47, 2004.
38. Van de Wetering M, Sancho E, Verweij C, De Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R and Clevers H: The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250, 2002.
39. Yamada Y, Yoshimi N, Hirose Y, Kawabata K, Matsunaga K, Shimizu M, Hara A and Mori H: Frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 60: 3323-3327, 2000.
40. Yamada Y, Yoshimi N, Hirose Y, Matsunaga K, Katayama M, Sakata K, Shimizu M, Kuno T and Mori H: Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 61: 1874-1878, 2001.
41. Mori H, Hata K, Yamada Y, Kuno T and Hara A: Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem Biol Interact 155: 1-9, 2005.
42. Femia AP, Bendinelli B, Giannini A, Salvadori M, Pinzani P, Dolara P and Caderni G: Mucin-depleted foci have beta-catenin gene mutations, altered expression of its protein, and are dose- and time-dependent in the colon of 1,2-dimethylhydrazine-treated rats. Int J Cancer 116: 9-15, 2005.
43. Takahashi M and Wakabayashi K: Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 95: 475-480, 2004.
44. He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F and Jablons DM: Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 24: 3054-3058, 2005.
45. Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K and Shinomura Y: Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24: 7946-7952, 2005.
46. Hamada T, Goto M, Tsutsumida H, Nomoto M, Higashi M, Sugai T, Nakamura S and Yonezawa S: Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing. Cancer Lett 227: 175-184, 2005.
47. Siedow A, Szyf M, Gratchev A, Kobalz U, Hanski ML, Bumke-Vogt C, Foss HD, Riecken EO and Hanski C: De novo expression of the Muc2 gene in pancreas carcinoma cells is triggered by promoter demethylation. Tumour Biol 23: 54-60, 2002.
48. Ho JJ, Han SW, Pan PL, Deng G, Kuan SF and Kim YS: Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells. Int J Oncol 22: 273-279, 2003.
49. Mesquita P, Peixoto AJ, Seruca R, Hanski C, Almeida R, Silva F, Reis C and David L: Role of site-specific promoter hypomethylation in aberrant MUC2 mucin expression in mucinous gastric carcinomas. Cancer Lett 189: 129-136, 2003.
50. Riede E, Gratchev A, Foss HD, Mann B, Buhr HJ and Hanski C: Increased methylation of promotor region suppresses expression of MUC2 gene in colon carcinoma cells. Langenbecks Arch Chir Suppl Kongressbd 115: 299-302, 1998.
51. Gratchev A, Siedow A, Bumke-Vogt C, Hummel M, Foss HD, Hanski ML, Kobalz U, Mann B, Lammert H, Mansmann U, Stein H, Riecken EO and Hanski C: Regulation of the intestinal mucin MUC2 gene expression in vivo: evidence for the role of promoter methylation. Cancer Lett 168: 71-80, 2001.
52. Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR and Rashid A: CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 160: 1823-1830, 2002.
53. Luo L, Chen WD and Pretlow TP: CpG island methylation in aberrant crypt foci and cancers from the same patients. Int J Cancer 115: 747-751, 2005.
54. Pereira MA, Tao L, Wang W, Li Y, Umar A, Steele VE and Lubet RA: Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis 25: 1917-1923, 2004.
55. Kim YD, Kwon EJ, Park DW, Song SY, Yoon SK and Baek SH: Interleukin-1beta induces MUC2 and MUC5AC synthesis through cyclooxygenase-2 in NCI-H292 cells. Mol Pharmacol 62: 1112-1118, 2002.
56. Enss ML, Cornberg M, Wagner S, Gebert A, Henrichs M, Eisenblatter R, Beil W, Kownatzki R and Hedrich HJ: Pro-inflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm Res 49: 162-169, 2000.
57. Koo JS, Kim YD, Jetten AM, Belloni P and Nettesheim P: Overexpression of mucin genes induced by interleukin-1 beta, tumor necrosis factor-alpha, lipopolysaccharide, and neutrophil elastase is inhibited by a retinoic acid receptor alpha antagonist. Exp Lung Res 28: 315-332, 2002.
58. Shaoul R, Okada Y, Cutz E and Marcon MA: Colonic expression of MUC2, MUC5AC, and TFF1 in inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 38: 488-493, 2004.
59. Buisine MP, Desreumaux P, Debailleul V, Gambiez L, Geboes K, Ectors N, Delescaut MP, Degand P, Aubert JP, Colombel JF and Porchet N; Abnormalities in mucin gene expression in Crohn's disease. Inflamm Bowel Dis 5: 24-32, 1999.
60. Buisine MP, Devisme L, Savidge TC, Gespach C, Gosselin B, Porchet N and Aubert JP: Mucin gene expression in human embryonic and fetal intestine. Gut 43: 519-524, 1998.